Parking B garage

New Parking Garage Opens May 1

Located just north of the Center for Care and Discovery, our new eight-floor garage adds more than 1,800 parking spaces to the medical campus.

Jean and Danny Martinez

Making Beautiful Music

With medication controlling her debilitating Parkinson’s symptoms, Jean Martinez can once again enjoy a cherished family hobby.

James Bell with docs

Beating Back the Widow Maker

James Bell had to be resuscitated several times after a blocked artery triggered a heart attack. The quick, coordinated efforts by emergency staff and interventional cardiologists opened Bell's artery and helped him return to a normal life.

Inquiry and Impact

The University of Chicago Capital Campaign

This ambitious campaign will support faculty and researchers who are shaping fields of inquiry, and will provide resources for scientists, physicians and students to ask and answer questions that are among the most challenging in medicine.

Mya Ludlow 10th birthday

Comer Children's Hospital Celebrates 10th Anniversary

Thanks to expert care at the University of Chicago Medicine Comer Children's Hospital, Mya Ludlow is celebrating her 10th birthday in 2015. Learn more about the impact of our first decade.

Specialties and Departments

View all specialties and departments
The University of Chicago Medicine Center for Care and Discovery

Community Benefit Report

2013 Community Benefit ReportThe University of Chicago Medicine contributed 22.5 percent, or $283 million, of total operating expenses in community benefits and services to improve the health of the South Side and beyond. » Read the 2013 Community Benefit Report

Science Life RSS

Study adds diabetes drug to current state-of-the-art therapy for patients with ovarian cancer

The University of Chicago Medicine is leading a clinical trial that will add metformin, a drug commonly used for type II diabetes, to the most effective current therapy for patients with stage 3 or stage 4 ovarian cancer.


Costs mount for targeted cancer therapies

Two-thirds of all US cancer patients taking intravenous or oral targeted drugs survive at least 5 years after diagnosis. But this comes at a cost, as a new study shows.